NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Testis
Testis · 9,810 new · 630 deaths (ACS 2026) · mortality 0.3 per 100k · 5-yr RS 94.6% (SEER)
Mortality 0.3 per 100k (SEER / ACS common-sites). Never an artboard percent.
Lifetime ≈ 0.4% among men (SEER Stat Facts). 325,990 men living with testicular cancer in 2023. No encoded screening interval.
325,990 men living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 33 · at death 40 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence men 6.1 per 100k · mortality men 0.3 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among men aged 20 to 34. Deaths highest among men aged 20–34. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases rising 0.7% each year (2014–2023). Death rates rising 2.3% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Non-Hispanic American Indian/Alaska Native men 7.2 per 100k. Highest death rate: Non-Hispanic American Indian/Alaska Native men 0.6 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | 6.8 | — | 0.4 | — |
| Non-Hispanic American Indian/Alaska Native | 7.2 | — | 0.6 | — |
| Non-Hispanic Asian/Pacific Islander | 2.6 | — | 0.1 | — |
| Non-Hispanic Black | 1.6 | — | 0.1 | — |
| Non-Hispanic White | 7.2 | — | 0.3 | — |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
USPSTF 2011 D · Asymptomatic adolescent or adult men · Do not screen
Cited only. No screening interval and no unpublished coefficient. USPSTF-testis-2011
ACS early-detection pointer
ACS 2025 · Men considering testicular self-exam · ACS (2025): some doctors recommend that all men examine their testicles monthly after puberty; each man has to decide for himself whether to do this. Complementary to the cited USPSTF 2011 D statement. No self-exam interval is encoded.
Cited ACS statement only. Not a screening engine. ACS-testis-detect
Surveillance pointer
ACS-testis-follow 2025 · cited only · ACS living-as-a-survivor page names close follow-up after testicular-cancer treatment, with exams, imaging, and tumor-marker tests for non-seminoma. An ASCO tumor-marker schedule is named on that page; those months are not encoded. Not a tumor-marker or imaging-calendar engine. Fertility and testosterone stay on the extra source only.
Named public source only. Not a personal follow-up calendar. ACS-testis-follow
Surveillance pointer
ACS-testis-second 2025 · cited only · ACS second-cancers page names regular visits after testicular-cancer treatment and says experts do not recommend additional testing to look for second cancers in people without symptoms. Remaining-testicle self-exam is named, not encoded. Complementary to the living-as pointer. Official relative-risk figures are not restated. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-testis-second
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names low testosterone after orchiectomy or pelvic radiation, osteoporosis after hormone-affecting treatment, and fertility effects after chemo or pelvis, belly, or spine radiation. Those names are not encoded. Complementary to the living-as pointer. Fertility and testosterone stay named only. Not a fertility-preservation or testosterone engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Echoes are named after cardiotoxic chemo. Those plans and tests are not encoded. Complementary to the prostate printout. Fertility and testosterone stay named only. Not a tumor-marker or remaining-testicle self-exam engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ACS-testis-follow 2025 · empty on purpose · ACS living-as-a-survivor page names radiation and chemo side effects that may last the rest of your life. Those late effects are not encoded. Fertility and testosterone stay on the extra source only. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-testis-follow
Toxicity pointer
ACS-testis-second 2025 · empty on purpose · ACS second-cancers page names later cancers after testicular-cancer treatment, including after radiation or chemo. Those second-cancer risks are not encoded. Official relative-risk figures are not restated. Complementary to the living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-testis-second
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later low testosterone, osteoporosis, and fertility effects after orchiectomy or pelvic treatment. Those late effects are not encoded. Fertility and testosterone stay named only. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after pelvis treatment. Echoes are named after cardiotoxic chemo. Those named tests are not encoded. Complementary to the prostate printout. Fertility and testosterone stay named only. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — Prostate
Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, and nausea. Late: radiation proctitis and cystitis, incontinence, fertility and sexual side effects, low testosterone, osteoporosis, heart problems after ADT, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: lingering rectal or bladder symptoms after 3 to 6 months; echoes after cardiotoxic chemo; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. First-row prostate toxicity stays empty on purpose. Not a PSA-kinetics or testosterone engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
ACS follow-up tests named here
Echoes after cardiotoxic chemo
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS pelvis / prostate names only. Complementary ACS long-term page is named, not encoded. First-row prostate toxicity stays empty on purpose. No invented trial percent.
Open Prostate printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-stub-testis · stub · none · v2-stub-testis
Stage table is not encoded for this stub. All-stage 5-year RS is 94.6% (SEER common sites).
Percent of cases by stage is not encoded. No official Stat Facts stage table.
lifetime
Testis birth-to-death (men)
≈ 0.4%
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
not computed — v2 stubCited ACS/SEER population pin only
screening
USPSTF 2011 D — do not screen asymptomatic men
Cited USPSTF 2011 D and ACS 2025 self-exam decision note. No self-exam interval is encoded.
not encoded
surveillance
ACS follow-up cited — testis months not encoded
Cited ACS living-as-a-survivor page only. An ASCO tumor-marker schedule is named, not encoded. Fertility stays an extra source.
not encoded
toxicity
ACS late effects cited — testis months not encoded
Empty on purpose. Fertility and testosterone stay on the extra source only.
not encoded
Noah · Plan — skin cancer
not computed — v2 stubCited ACS/SEER population pin only
screening
USPSTF 2011 D — do not screen asymptomatic men
Cited USPSTF 2011 D and ACS 2025 self-exam decision note. No self-exam interval is encoded.
not encoded
surveillance
ACS follow-up cited — testis months not encoded
Cited ACS living-as-a-survivor page only. An ASCO tumor-marker schedule is named, not encoded. Fertility stays an extra source.
not encoded
toxicity
ACS late effects cited — testis months not encoded
Empty on purpose. Fertility and testosterone stay on the extra source only.
not encoded
Walter · S1 prostate
not computed — v2 stubCited ACS/SEER population pin only
screening
USPSTF 2011 D — do not screen asymptomatic men
Cited USPSTF 2011 D and ACS 2025 self-exam decision note. No self-exam interval is encoded.
not encoded
surveillance
ACS follow-up cited — testis months not encoded
Cited ACS living-as-a-survivor page only. An ASCO tumor-marker schedule is named, not encoded. Fertility stays an extra source.
not encoded
toxicity
ACS late effects cited — testis months not encoded
Empty on purpose. Fertility and testosterone stay on the extra source only.
not encoded
Priya · average-risk
not computed — v2 stubCited ACS/SEER population pin only
screening
USPSTF 2011 D — do not screen asymptomatic men
Cited USPSTF 2011 D and ACS 2025 self-exam decision note. No self-exam interval is encoded.
not encoded
surveillance
ACS follow-up cited — testis months not encoded
Cited ACS living-as-a-survivor page only. An ASCO tumor-marker schedule is named, not encoded. Fertility stays an extra source.
not encoded
toxicity
ACS late effects cited — testis months not encoded
Empty on purpose. Fertility and testosterone stay on the extra source only.
not encoded
Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.